Product
H3 mRNA / LNP Vaccine
1 clinical trial
1 indication
Indication
Influenza ImmunizationClinical trial
A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of One Monovalent Modified Influenza mRNA Vaccine Encapsulated in LNP, in Adults Aged 18 to 49 Years and 60 Years and Above.Status: Completed, Estimated PCD: 2024-03-14